Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person15
Soleus Capital Master Fund, L.P.
Company
BIGGER CAPITAL FUND L P
Company
L1 Capital Global Opportunities Master Fund, Ltd.
Company
Bain Capital Life Sciences Fund, L.P.
Company
Silver Point Capital L.P.
Company
Saba Capital Management, L.P.
Company
LMP CAPITAL & INCOME FUND INC.
Company
RA CAPITAL MANAGEMENT, L.P.
Company
Linden Capital L.P.
Company
HPS Corporate Capital Solutions Fund
Company
Adage Capital Management, L.P.
Company
FR Capital Holdings, L.P.
Company
CAPITAL ONE FUNDING, LLC
Company
QUMRA CAPITAL II, L.P.
Company
First Trust Capital Management L.P.
Company
Primary record8
Evolus, Inc. filed SCHEDULE 13G
, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage set for
Processa Pharmaceuticals, Inc. filed SCHEDULE 13G
, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage set for
Inspire Medical Systems, Inc. filed SCHEDULE 13G/A
on August 3, 2026 (the "Form 10-Q"). Soleus Capital, LLC DE 0.00 1931436.00 0.00 1931436.00 1931436.00 N 6.7 OO (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole
Soleus Capital Master Fund, L.P. filed SCHEDULE 13G/A
, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage set for
PALISADE BIO, INC. filed SCHEDULE 13G/A
on August 10, 2026 (the "Form 10-Q"). Soleus Capital, LLC DE 0.00 13063687.00 0.00 13063687.00 13063687.00 N 7.5 OO (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the
RIGEL PHARMACEUTICALS INC filed SCHEDULE 13G/A
on August 4, 2026 (the "Form 10-Q"). Soleus Capital, LLC DE 0.00 1843504.00 0.00 1843504.00 1843504.00 N 9.9 OO (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole
CERUS CORP filed SCHEDULE 13G/A
, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage set for
IMMUNIC, INC. filed SCHEDULE 13G/A
, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The number of shares r